Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 19/20 | 0.75 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | ESRRB | O95718 | 2/20 | 0.44 |
| ▸ | ESRRA | P11474 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922863 | 0.86 | ESR1 (0.81) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL27638541 | 0.86 | ESR2 (0.62) | ESR1ESR2 | |
| SCHEMBL3925261 | 0.86 | ESR1 (0.85) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3927237 | 0.86 | ESR1 (1.00) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3922478 | 0.84 | ESR1 (0.81) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3929572 | 0.84 | ESR1 (0.81) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3924811 | 0.81 | ESR1 (0.77) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3923804 | 0.81 | ESR1 (0.76) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3925043 | 0.81 | ESR1 (0.72) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3929956 | 0.79 | ESR1 (1.00) | ESR1ESR2ESRRBESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-7084276-B2 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-08-01 | — | — | US | claimed |
| EP-1628961-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | Wyeth (US) | 2006-03-01 | — | — | EP | claimed |
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | claimed |
| WO-2004103973-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | WYETH (US) | 2004-12-02 | — | — | WO | claimed |
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7084276-B2 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1628961-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | Wyeth (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103973-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885CYP17A1 56/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR1 4/4885ESR2 5/4885CYP17A1 13/4885 |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885CYP17A1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.